Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT05275868
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Onc. Dept, New York, New York, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT05275855
- Locations
- 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom
A 24-week rPMS Study in Real-world Setting for Enerzair
Recruiting
- Conditions
- Asthma
- Interventions
- Other: Enerzair 150/50/80 μgOther: Enerzair 150/50/160 μg
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 600
- Registration Number
- NCT05274425
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05272059
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Phase 4
Completed
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT05269966
- Locations
- 🇮🇳
Novartis Investigative Site, New Delhi, India
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
- Conditions
- Polycythemia Vera
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05269771
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Phase 2
Recruiting
- Conditions
- Lupus Nephritis
- Interventions
- Drug: Placebo + standard of care
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 240
- Registration Number
- NCT05268289
- Locations
- 🇺🇸
AKDHC Medical Research ServicesLLC, Phoenix, Arizona, United States
🇺🇸Kaiser Permanente Fontana, Fontana, California, United States
🇺🇸Univ Calif Irvine, Irvine, California, United States
Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting
Terminated
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Other: Brolucizumab
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3
- Registration Number
- NCT05266495
- Locations
- 🇦🇪
Novartis Investigative Site, Abu Dhabi, United Arab Emirates
Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf
Completed
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Other: OfatumumabOther: Ocrelizumab
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 168
- Registration Number
- NCT05266469
- Locations
- 🇦🇪
Novartis Investigative Site, Sharjah, United Arab Emirates
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT05252585
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath